First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. (September 2022)

• Record Type: Journal Article
• Authors: Ma, Yuxiang; Zhao, Hongyun; Xue, Jinhui; Liu, Li; Yang, Nong; Zhang, Yang; Yang, Haiyan; Hong, Shaodong; Xiong, Yi; Zhang, Zhonghan; Zeng, Liang; Pan, Hui; Zhou, Chunhua; Zhang, Yongchang; Wang, Xunqiang; Han, Xi; Wan, Xiaojing; Shao, Yang; Liu, Jingwen; Yang, Yunpeng; Huang, Yan; Zhao, Yuanyuan; Fang, Wenfeng; Li, Su; Zhang, Li
• Is Part Of: European journal of cancer. Volume 173(2022)
• Page Start: 238
• Page End: 249
• Publication Date: 2022-09
• Subjects: TQ-B3139 -- ALK rearrangement -- Efficacy -- Safety -- Next-generation sequencing; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2022.06.037
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: TQ-B3139 is a novel ALK tyrosine kinase inhibitor (TKI) against a broad range of ALK mutations. The aim of this first-in-human phase I trial was to investigate the safety, tolerability, pharmacokinetics, and clinical efficacy of TQ-B3139 in ALK or ROS1 positive advanced NSCLC patients. Methods: Following a 3 + 3 design, patients received escalating daily dose of TQ-B3139 (50–800 mg) continuously in 28-day cycles. Expansion stage started at dose of 200 mg twice daily (BID). The primary objectives were the safety, dose-limited toxicities (DLT) and recommended phase II dose (RP2D); secondary objectives included pharmacokinetics and antitumor activity. Non-obligatory tumor samples at baseline were collected and sequenced. Results: The study enrolled 63 patients. Fifty-nine (93.4%) patients experienced treatment-related adverse events (TRAEs), mostly grade 1–2 vomiting (79.3%), diarrhea (76.1%) or nausea (68.2%). 1 (1/6) DLT occurred at 600 mg BID and 1 (1/3) at 800 mg BID. Based on safety and pharmacokinetics data, the RP2D was selected as 600 mg BID. At a dose level ≥200 mg BID, the overall response rate (ORR) was 76.7% (33/43), and the median progression free survival (mPFS) was 25.2 months (95%CI 11.9-NR) for TKI-naive patients. For TKI-treated patients, the ORR was 37.5% (6/16), and the mPFS was 5.4 months (95%CI 3.6–9.1). The ORR was 66.7% (2/3) in patients with ROS1 fusion at dose level ≥200 mg BID. In patients with measurable brain metastases, the intracranial ORR was 70% (7/10), with median intracranial PFS of 15.9 months. In TKI-treated patients, variant 3 and TP53 alteration were associated with poor PFS. Conclusions: TQ-B3139 was well-tolerated and exhibited promising anti-tumor activities in patients with ALK and ROS1 positive advanced NSCLC. Clinical trial number: NCT03099330. Highlights: TQ-B3139 is a novel second generation ALK-TKI, also inhibiting ROS and c-Met. TQ-B3139 has promising antitumor activity and tolerated toxicity. Favorable intracranial ORR and PFS were observed in ALK + NSCLC patients. Variant3 and TP53 alteration were associated with poor PFS in TKI-treated patients.